• Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline
Print

News

  • IGBA Welcomes update to ICH M7 on Assessment and Control of Nitrosamine Impurities (June 2024)

    The International Generic and Biosimilar Medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its decision to develop an Addendum to the ICH M7 Guideline on

    Read More
  • IGBA Re-Elected to ICH Management Committee (June 2024)

    The International Generic and Biosimilar Medicines Association (IGBA) welcomes the decision of the ICH General Assembly to re-elect the IGBA as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).

    Read More
  • Joint Industry Statement for 77th World Health Assembly (May 2024)

    Non-communicable diseases (NCDs) are on the rise and impacting the lives of people around the world. IGBA is pleased to join IFPMA, DITTA, GSCF, WHL, and PATH in a formal statement at WHA on the need for multistakeholder solutions to

    Read More
  • IGBA’s CEO Advisory Committee advances strategic focus on access to medicines (May 2024)

    Chief Executive Officers of the world’s largest generic and biosimilar medicines companies met in Vienna on 15 May 2024 to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). The generics and biosimilars sector, which supplies 70

    Read More
  • IGBA Comments to the 13 March 2024 Proposal for negotiating text of the Pandemic Agreement (April 2024)

    As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems. In an open

    Read More
  • Joint Industry Statement for WHO's Executive Board Meeting 154 (January 2024)

    We welcome the Executive Board (EB) report on noncommunicable diseases (NCDs) and WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. With childhood obesity and diabetes on an alarming rise, alongside population ageing, urbanization, climate

    Read More
  • IGBA General Statement on WHO's Executive Board Meeting 154 (January 2024)

    The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking

    Read More
  • IGBA Open Letter concerning the INB negotiations of the Pandemic Agreement (January 2024)

    The generic and biosimilar medicines industry globally, represented by the International Generic and Biosimilar medicines Association (IGBA), supplies the overwhelming majority of prescription medicines to patients worldwide, and strongly supports ongoing multilateral efforts to achieve a robust WHO Pandemic Agreement.

    Read More
  • IGBA Comments to the 30 October 2023 Proposal for negotiating text of the Pandemic Agreement (January 2024)

    IGBA welcomes the opportunity to provide comments to the 30 October 2023 proposal for negotiating text of the WHO Pandemic Agreement. As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States

    Read More
  • IGBA announces leadership change (January 2024)

    The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Suzette Kox, the first IGBA Secretary General, has passed on the baton to Dr. Susana Almeida.

    Read More
  • Vinita Gupta and Lucas Sigman appointed 2024 Chair and Vice-Chair of the IGBA CEO Advisory Committee (December 2023)

    The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Vinita Gupta, CEO of Lupin, was appointed Chair and Lucas Sigman, CEO of Insud Pharma, Vice-Chair.

    Read More
  • IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care (November 2023)

    Geneva, November 13, 2023 – In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Print

Our Mission and Vision

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

Introduction

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Share this page!

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on: Twitter - LinkedIn - YouTube

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site